Teva Wins FDA Approval for Biosimilar of Amgen's Xgeva
AMGN sits 55% above its 52-week low of $269.77.
Summary
Teva has received FDA approval for a biosimilar version of Amgen's Xgeva (denosumab), introducing direct competition for the bone-targeting agent. Xgeva is a significant product for Amgen, and biosimilar entry typically leads to price erosion and market share loss. This approval follows a series of challenges for Amgen, including the FDA's proposal to withdraw Tavneos and the recent cardiovascular setback for pelacarsen. Investors will watch for Teva's launch timing and pricing strategy, which will determine the near-term revenue impact on Amgen's franchise.
At the time of this announcement, AMGN was trading at $418.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.1B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.